FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Peter Svensson

Research Profile

Chemicals & Drugs

Geographic Areas

Sweden

Concepts & Ideas

Disorders

Physiology

Procedures

Living Beings

Outpatients

Co-author Network

Publications

TOP 3
Bartosz Grzymala-Lubanski; Henrik Renlund; Sara Själander; Peter J Svensson; Anders Själander
Computer aided warfarin dosing in the Swedish national quality registry AuriculA - Algorithmic suggestions are performing better than manually changed doses.
J Gustav Smith; Peter J Svensson; Mattias Wieloch; Oscar Ö Braun; Sasha Koul; Jonathan Lumsden; Jenny Ohman; Emil Rydell; Fredrik Scherstén; Jesper van der Pals
Triple antithrombotic therapy following an acute coronary syndrome: prevalence, outcomes and prognostic utility of the HAS-BLED score.
Signy V Sveinsdottir; Anders Gottsäter; Nazim Isma; Ymir Saemundsson; Peter J Svensson
Evaluation of recurrent venous thromboembolism in patients with Factor V Leiden mutation in heterozygous form.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Peter Svensson (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Bartosz Grzymala-Lubanski; Henrik Renlund; Sara Själander; Peter J Svensson; Anders Själander
Computer aided warfarin dosing in the Swedish national quality registry AuriculA - Algorithmic suggestions are performing better than manually changed doses.
Thrombosis research 2013;131(2):130-4.
2012: J Gustav Smith; Peter J Svensson; Mattias Wieloch; Oscar Ö Braun; Sasha Koul; Jonathan Lumsden; Jenny Ohman; Emil Rydell; Fredrik Scherstén; Jesper van der Pals
Triple antithrombotic therapy following an acute coronary syndrome: prevalence, outcomes and prognostic utility of the HAS-BLED score.
EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology 2012;8(6):672-8.
2012: Signy V Sveinsdottir; Anders Gottsäter; Nazim Isma; Ymir Saemundsson; Peter J Svensson
Evaluation of recurrent venous thromboembolism in patients with Factor V Leiden mutation in heterozygous form.
Thrombosis research 2012;130(3):467-71.
2011: Karl M Jönsson; Ulf Nyman; Gunnar Sterner; Sölve Elmståhl; Gunnar Engström; Mattias Wieloch; Peter J Svensson
Glomerular filtration rate in patients with atrial fibrillation on warfarin treatment: a subgroup analysis from the AURICULA registry in Sweden.
Thrombosis research 2011;128(4):341-5.
2011: Mattias Wieloch; Niclas Eriksson; Viveka Frykman; Mårten Rosenqvist; Anders Själander; Peter J Svensson
Anticoagulation control in Sweden: reports of time in therapeutic range, major bleeding, and thrombo-embolic complications from the national quality registry AuriculA.
European heart journal 2011;32(18):2282-9.
2009: Nazim Isma; Peter J Svensson; Anders Gottsäter; Bengt Lindblad
Prospective analysis of risk factors and distribution of venous thromboembolism in the population-based Malmö Thrombophilia Study (MATS).
Thrombosis research 2009;124(6):663-6.
2009: Elisabet Zia; Gunnar Engström; Peter J Svensson; Bo Norrving; Hélène Pessah-Rasmussen
Three-year survival and stroke recurrence rates in patients with primary intracerebral hemorrhage.
Stroke; a journal of cerebral circulation 2009;40(11):3567-73.
2009: Mattias Wieloch; Andreas Hillarp; Karin Strandberg; Camilla Nilsson; Peter J Svensson
Comparison and evaluation of a Point-of-care device (CoaguChek XS) to Owren-type prothrombin time assay for monitoring of oral anticoagulant therapy with warfarin.
Thrombosis research 2009;124(3):344-8.
2007: Karin Strandberg; Peter J Svensson; Ann-Kristin Ohlin
Venous thromboembolism in carriers of the Factor V Leiden mutation and in patients without known thrombophilic risk factor; prediction of recurrence and APC-PCI complex concentration and/or soluble thrombomodulin antigen and activity.
Thrombosis research 2007;121(2):145-51.
2006: Johan Stenflo; Margareta Kjellberg; Karin Strandberg; Peter J Svensson; Tilo Kölbel; Bengt Lindblad
The complex between activated protein C and protein C inhibitor: A clinically useful indicator of aortic aneurysms?
Blood cells, molecules & diseases 2006;36(2):118-21.
2005: Karin Strandberg; Johan Stenflo; C Nilsson; Peter J Svensson
APC-PCI complex concentration is higher in patients with previous venous thromboembolism with Factor V Leiden.
Journal of thrombosis and haemostasis : JTH 2005;3(11):2578-80.
2005: Anders Björkman; Isabella M Burtscher; Peter J Svensson; Andreas Hillarp; Jack Besjakov; Göran Benoni
Factor V Leiden and the prothrombin 20210A gene mutation and osteonecrosis of the knee.
Archives of orthopaedic and trauma surgery 2005;125(1):51-5.
2004: Anders Björkman; Peter J Svensson; Andreas Hillarp; Isabella M Burtscher; Anders Rünow; Göran Benoni
Factor V leiden and prothrombin gene mutation: risk factors for osteonecrosis of the femoral head in adults.
Clinical orthopaedics and related research 2004;(425):168-72.
2001: Ola Björgell; Paul E Nilsson; Jan-Ake Nilsson; Peter J Svensson
On difficulties in diagnosing deep vein thrombosis in daily clinical work and research practice.
Clinical laboratory 2001;47(7-8):369-75.
2000: Olof Grip; Peter J Svensson; Stefan Lindgren
Inflammatory bowel disease promotes venous thrombosis earlier in life.
Scandinavian journal of gastroenterology 2000;35(6):619-23.
2000: Ola Björgell; Paul E Nilsson; Jan-Ake Nilsson; Peter J Svensson
Location and extent of deep vein thrombosis in patients with and without FV:R 506Q mutation.
Thrombosis and haemostasis 2000;83(5):648-51.
2000: Henrik Ekberg; Peter J Svensson; Mecislovas Simanaitis; Björn Dahlbäck
Factor V R506Q mutation (activated protein C resistance) is an additional risk factor for early renal graft loss associated with acute vascular rejection.
Transplantation 2000;69(8):1577-81.
1999: L Roussos; C Flor n; J Carlson; Peter J Svensson; A Wallmark; H Ekberg
Increased prevalence of apolipoprotein E3/E4 genotype among Swedish renal transplant recipients.
Nephron 1999;83(1):25-30.
1999: Pelle G Lindqvist; Peter J Svensson; K Marsaál; L Grennert; M Luterkort; Björn Dahlbäck
Activated protein C resistance (FV:Q506) and pregnancy.
Thrombosis and haemostasis 1999;81(4):532-7.
1999: Ola Björgell; Paul E Nilsson; Peter J Svensson; D Bergqvist
A new scoring system for the detailed description of the distribution and thrombotic burden in deep leg vein thrombosis.
Angiology 1999;50(3):179-87.
1998: B Zoller; Peter J Svensson; B Dahlback; Andreas Hillarp
The A20210 allele of the prothrombin gene is frequently associated with the factor V Arg 506 to Gln mutation but not with protein S deficiency in thrombophilic families.
Blood 1998;91(6):2210-1.
1998: Pelle G Lindqvist; Peter J Svensson; Björn Dahlbäck; Karel Marsál
Factor V Q506 mutation (activated protein C resistance) associated with reduced intrapartum blood loss--a possible evolutionary selection mechanism.
Thrombosis and haemostasis 1998;79(1):69-73.
1997: Peter J Svensson; Göran Benoni; H Fredin; Ola Björgell; P Nilsson; U Hedlund; G Nylander; D Bergqvist; Björn Dahlbäck
Female gender and resistance to activated protein C (FV:Q506) as potential risk factors for thrombosis after elective hip arthroplasty.
Thrombosis and haemostasis 1997;78(3):993-6.
1997: Andreas Hillarp; Bengt Zöller; Peter J Svensson; Björn Dahlbäck
The 20210 A allele of the prothrombin gene is a common risk factor among Swedish outpatients with verified deep venous thrombosis.
Thrombosis and haemostasis 1997;78(3):990-2.
1997: Peter J Svensson; Bengt Zöller; Ingrid Mattiasson; Björn Dahlbäck
The factor VR506Q mutation causing APC resistance is highly prevalent amongst unselected outpatients with clinically suspected deep venous thrombosis.
Journal of internal medicine 1997;241(5):379-85.
1997: Peter J Svensson; Bengt Zöller; Björn Dahlbäck
Evaluation of original and modified APC-resistance tests in unselected outpatients with clinically suspected thrombosis and in healthy controls.
Thrombosis and haemostasis 1997;77(2):332-5.
1994: Bengt Zöller; Peter J Svensson; X He; Björn Dahlbäck
Identification of the same factor V gene mutation in 47 out of 50 thrombosis-prone families with inherited resistance to activated protein C.
The Journal of clinical investigation 1994;94(6):2521-4.
1994: J Holm; Bengt Zöller; Peter J Svensson; E Berntorp; Leif Erhardt; Björn Dahlbäck
Myocardial infarction associated with homozygous resistance to activated protein C.
Lancet 1994;344(8927):952-3.
1994: Peter J Svensson; Björn Dahlbäck
Resistance to activated protein C as a basis for venous thrombosis.
The New England journal of medicine 1994;330(8):517-22.
1993: Björn Dahlbäck; M Carlsson; Peter J Svensson
Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: prediction of a cofactor to activated protein C.
Proceedings of the National Academy of Sciences of the United States of America 1993;90(3):1004-8.